title: Oligonucleotides decoy to NF-kappaB: becoming a reality?
abstract: In the last two decades, frontiers in new drug development are represented by genetic code inhibitors. Nuclear factor-kappaB (NF-κB) is a transcription factor playing critical roles in many inflammatory/immune diseases. Decoy oligonucleotides (decoy ONs) epitomize an ideal pharmacological tool to selectively block NF-κB activation. Their use is currently being investigated in several chronic inflammatory-based diseases. However, decoy ONs' clinical use is strongly hampered by several issues. Chemical modifications and/or delivery systems have been investigated to overcome some of these limits. This review describes the successful preclinical and clinical applications of decoy ON against NF-κB in inflammatory-based diseases.
authors: Department of Experimental Pharmacology, School of Biotechnological Sciences, University of Naples Federico II, Naples, Italy. dadestef@unina.it
authors: Daniela
authors: D
authors: De Stefano
mesh_terms: D000818:Animals; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D008954:Models, Biological; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D009841:Oligonucleotides / Q000627:therapeutic use*
chemical_list: D016328:NF-kappa B; D009841:Oligonucleotides